Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Oppat

Vascular Surgery Novi, MI Medical Doctor

NPI 1902873086 CMS profile 86768

26850 Providence Pkwy Ste 405, Novi, MI 48374

Open in the dashboard

General payments

$8,396

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Oppat of Novi, MI is reported in the CMS Open Payments database as having received $8,396 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,888 18
2024 General $1,183 14
2023 General $602 9
2022 General $396 8
2021 General $1,028 9
2020 General $175 5
2019 General $3,124 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Oppat
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to William Oppat were reported at $1,888. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year William Oppat Vascular Surgery median Middle half National median
2019 $3,124 $796 $226–$2,363 $163
2020 $175 $348 $118–$1,110 $114
2021 $1,028 $471 $158–$1,421 $132
2022 $396 $725 $222–$2,183 $149
2023 $602 $836 $257–$2,440 $160
2024 $1,183 $909 $252–$2,619 $164
2025 $1,888 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NuVasive, Inc. $1,882 9 payments
  2. Endologix, Inc. $1,764 18 payments
  3. W. L. Gore & Associates, Inc. $1,694 18 payments
  4. Inari Medical, Inc. $1,197 5 payments
  5. Medtronic USA, Inc. $918 5 payments
  6. Abbott Laboratories $143 3 payments
  7. Bard Peripheral Vascular, Inc. $98 1 payment
  8. AngioDynamics, Inc. $91 1 payment
  9. Stryker Corporation $80 1 payment
  10. LeMaitre Vascular, Inc. $78 1 payment
  11. Other $450 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,249 72 payments
  2. Travel and Lodging $4,146 13 payments
Products named General payments · program years 2019–2025
  1. XLIF $1,769 8 payments
  2. ALIF $1,726 6 payments
  3. FLOWTRIEVER CATHETER, S $1,277 6 payments
  4. CT THROMBECTOMY SYSTEM KIT $1,277 6 payments
  5. Alto Abdominal Stent Graft System $1,067 12 payments
  6. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $1,049 8 payments
  7. DIVERGENCE-L $918 5 payments
  8. ENDOCROSS Device $496 4 payments
  9. Torus Stent Graft System $496 4 payments
  10. GORE VIABAHN Endoprosthesis with Heparin $183 1 payment
  11. Other $1,414 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

230

Median for Vascular Surgery: 122

Drug cost

$57,684

Median for Vascular Surgery: $14,135

Branded share of claims

69.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 31 $27,449
Eliquis Apixaban Brand 34 $26,790
Cilostazol Generic 56 $1,926
Clopidogrel Clopidogrel Bisulfate Brand 94 $1,394
Atorvastatin Calcium Generic 15 $125

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$160,094

Medicare's payments for the services billed

Medicare patients

424

Average age 75

Services billed

1,194

198 women, 226 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 48%
Diabetes 42%
Chronic kidney disease 32%
Heart failure 29%
COPD 27%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record